Fig. 4From: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cellsIn vivo reconstitution of healthy human hematopoietic compartments in peripheral blood. Comparable profile between TEG001 and TEG-LM1 mock group of reconstituted healthy human hematopoietic cellular subsets, including CD14+ monocytes (a) B cells (b), T cells (c), and CD34+ progenitor cells (d) as measured by flow cytometry. Data represent mean ± SD of all mice per group (n = 10)Back to article page